Bruker (BRKR)
(Delayed Data from NSDQ)
$64.54 USD
+0.81 (1.27%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $64.54 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$64.54 USD
+0.81 (1.27%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $64.54 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth A Momentum C VGM
Zacks News
After Plunging 14% in 4 Weeks, Here's Why the Trend Might Reverse for Bruker (BRKR)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Bruker (BRKR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Bruker (BRKR) Up 9.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bruker (BRKR) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Bruker (BRKR) on solid BSI Nano Group growth potential and raised 2021 financial guidance.
Syneos Health (SYNH) Q2 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Syneos Health (SYNH) reported better-than-expected revenues for the second quarter of 2021 on strong segmental performance.
Illumina (ILMN) Q2 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Year-over-year improvement in segmental revenues in Q2 across all geographies exceeds Illumina's (ILMN) expectations.
Insulet (PODD) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Insulet (PODD) reports better-than-expected revenues for second-quarter 2021 on strong performance of Omnipod, both in U.S. and international markets.
Tandem Diabetes (TNDM) Q2 Earnings Rise Y/Y, Sales View Up
by Zacks Equity Research
Tandem Diabetes (TNDM) reports better-than-expected revenues for second quarter 2021 on strong domestic and international pump shipments driving the top line.
Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Grow
by Zacks Equity Research
Amedisys (AMED) reports better-than-expected earnings for the second quarter with strong performance in Home Health and Hospice segments.
Bruker (BRKR) Q2 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Bruker (BRKR) reports better-than-expected revenues for the second quarter of 2021 on strong segmental performance driving the top line.
Bruker (BRKR) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 10.00% and 6.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Qorvo (QRVO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Qorvo's (QRVO) fiscal first-quarter results are likely to reflect continued strength in its 5G mobile products and Wi-Fi 6 devices, and increased demand for defense solutions.
Bruker (BRKR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Bruker (BRKR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Microchip (MCHP) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Microchip's (MCHP) fiscal first-quarter results are likely to reflect robust uptake of microcontrollers amid uptick in demand across automotive, consumer, industrial, and medical end-markets.
IPG Photonics (IPGP) to Post Q2 Earnings: What to Expect?
by Zacks Equity Research
IPG Photonics' (IPGP) Q2 results are likely to reflect momentum in new end-markets and fiber lasers for urological and dental procedures.
ON Semiconductor (ON) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
ON Semiconductor's (ON) Q2 revenues are expected to have benefited from recovery in automotive and industrial sector.
FLEX Q1 Earnings and Revenues Surpass Estimates, Up Y/Y
by Zacks Equity Research
Flex (FLEX) Q1 results reflect continued strength in the Agility Solutions and Reliability Solutions segments.
Should You Buy Bruker (BRKR) Ahead of Earnings?
by Zacks Equity Research
Bruker (BRKR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Ultra Clean (UCTT) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Ultra Clean's (UCTT) Q2 results are likely to reflect solid demand for its semiconductor products and services, along with an expanding clientele.
MKS Instruments (MKSI) Q2 Earnings Top Estimates, Revenues Up
by Zacks Equity Research
MKS Instruments' (MKSI) Q2 results benefit from strength in the semiconductor market and recovery in advanced market revenues.
Cognizant's (CTSH) Q2 Earnings Beat, Revenues Increase Y/Y
by Zacks Equity Research
Cognizant's (CTSH) second-quarter 2021 results reflect robust performance across segments including Healthcare, Communications, Media and Technology.
Facebook's (FB) Q2 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Facebook's (FB) second-quarter 2021 performance gains from robust ad revenues and user-base expansion in international markets.
Arista (ANET) to Report Q2 Earnings: Is a Beat in the Offing?
by Zacks Equity Research
Solid demand for cloud networking solutions, technological innovations and considerable top-line growth are likely to have aided Arista's (ANET) earnings in the second quarter of 2021.
Can Bruker (BRKR) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Bruker (BRKR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amphenol (APH) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Amphenol's (APH) Q2 results reflect robust growth in the automotive, industrial, military and broadband end-markets.
Apple (AAPL) Q3 Earnings Beat, iPhone Strength Aids Top Line
by Zacks Equity Research
Apple's (AAPL) third-quarter fiscal 2021 results reflect robust performance of iPhone and Services segments.